ASSESSMENT OF IMPLEMENTING THE COMPASS TRIAL RESULTS IN ROUTINE CLINICAL PRACTICE IN ONTARIO, CANADA: INSIGHTS FROM THE CARDIOVASCULAR HEALTH IN AMBULATORY CARE RESEARCH TEAM (CANHEART) STUDY

The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial showed decrease in major adverse cardiovascular events (MACE) with low-dose rivaroxaban (riva) and ASA vs ASA alone in patients (pts) with a history of CAD and/or PAD. The aim of this study was to examine a) the